Company / Cash & Equivalents
PALVELLA THERAPEUTICS, INC. Cash & Equivalents History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$83.6M
FY2024
5-year range
$7.3M / $117.8M
FY2020-FY2024
Trend
+1037.4%
vs FY2023
Sector context
#156 of 207
Health Care
What the data says
Cash & Equivalents changed +1037% YoY in FY2024, a notable deviation from the 9-year average annual change of +123%.
Based on SEC 10-K filings.
$84M in FY2024 with a 5-year CAGR of +6.1%.
Improved from $39M to $84M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -10.8%
- 5-Year CAGR
- +6.1%
- 10-Year CAGR
- -
Sector benchmark
Bottom 25% in Health CareTop 75% of 207This company $83.6M Sector average $669.5M
▼
-87.5% below sector average
Key checks
Key Insights
- 5-year CAGR of +6.1%, indicating consistent growth.
- In FY2024, cash & equivalents increased 1037.4% year-over-year.
- Ranks #156 out of 207 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score 1.15 (distress zone, below 1.8 threshold)
- Strong profit margin: 43.7%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $83.6M | +1037.4% |
| FY2023 | $7.3M | -81.0% |
| FY2022 | $38.6M | -67.2% |
| FY2021 | $117.8M | +67.2% |
| FY2020 | $70.4M | +13.1% |
| FY2019 | $62.3M | -16.8% |
| FY2018 | $74.9M | +155.0% |
| FY2017 | $29.4M | +0.0% |
| FY2016 | $29.4M | +0.0% |
| FY2015 | $29.4M | +58.9% |
As of FY2024 · SEC 10-K Annual Filings · Updated Jun 30, 2026